Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $147.17M | $-408.35M | $-11.11 |
| 2024 | $125.59M | $-2.03B | $-63.54 |
| 2023 | $93.11M | $-1.47B | $-47.20 |
| 2022 | $55.55M | $-5.40B | $-173.87 |
| 2021 | $14.61M | $-1.25B | $-40.18 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-2.62 per share
Typical surprise +23.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-2.56 vs $-2.66beat
- Tue, May 5$-2.29 vs $-2.76beat
- Thu, Feb 19$-2.44 vs $-3.33beat
- Wed, Nov 12$-2.46 vs $-3.36beat
- Tue, Aug 12$-3.18 vs $-3.14miss
- Tue, May 13$-3.10 vs $-4.03beat
Estimates and results for GRAL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
GRALhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (3)
- Newsmarketbeat.com·1d ago·Positive
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.
View source ↗ - Newsseekingalpha.com·2d ago·Positive
GRAIL: Looking Beyond The NHS-Galleri Headline GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.
View source ↗ - Newsbenzinga.com·5d ago·Negative
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test GRAIL Inc. (NASDAQ:GRAL) on Friday said it is preparing for a pivotal regulatory event as the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel gears up to evaluate the healthcare company's flagship cancer diagnostic tool.
View source ↗